Venus Remedies Limited has secured marketing authorisation from Serbia for gemcitabine and docetaxel, widely used chemotherapy drugs beneficial in the treatment of various types of cancer. With this, the company has secured 511 marketing approvals for its oncology products across 66 countries. Oncology drugs constitute the largest proportion of the Serbian pharmaceutical market (projected to reach $397.40 million in 2023), where Venus Remedies has secured five marketing approvals, all ln the oncology space, The high prevalence of breast cancer, ovarian cancer, pancreatic cancer and cancers of the lung and Intestine is a key driver of the global oncology market, which was valued at $286.04 billion ln 2021 and is projected to reach $536.01 billion by 2029 at a compounded annual growth rate (CAGR) of 8.2% from 2021 to 2030.